Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only


Share this article
Share on facebook
Share on twitter
Share on email
Share on print

The metabolic and psychological effects of an insulin regimen change

The last few years have seen several new developments in the treatment and management of diabetes, including new insulin formulations and delivery methods, simpler blood sugar tests and people with diabetes taking greater responsibility for the management of their condition (Naess and Eriksen, 2002). Among the new treatment regimens that have emerged, the development of rapid- and long-acting insulin analogues using recombinant DNA technology represents a major advance in the treatment of diabetes (Barrio Castellanos, 2005). Insulin analogues can replicate endogenous basal and bolus (mealtime) insulin secretion ‘with unprecedented accuracy’ and reduce HbA1c levels (Barnett, 2002). Further therapeutic developments in the pipeline include trials of inhaled insulin as a non-invasive alternative to injected insulin (Amiel and Alberti, 2004). In this article Phillip Pickstock describes a retrospective questionnaire analysis assessing the effect of an insulin regimen change on treatment satisfaction and general wellbeing.

The basal–bolus insulin regimen is the most common one for people with type 1 diabetes. It involves long-acting (basal) insulin, which is injected at night, and an additional bolus injection of short-acting insulin before each meal. People with type 2 diabetes who have deteriorating glycaemic control may also follow a basal–bolus regimen. Before the advent of insulin analogues, the use of regular human insulin as the bolus component was widespread; its major disadvantage is that it causes a peak in plasma insulin concentration 1–2 hours after injection, unlike the short-lived prandial response seen in people without diabetes (Kumar and Clark, 1998). The rapid-acting insulin analogues (insulins lispro [Humalog; Eli Lilly], aspart [NovoRapid; Novo Nordisk] and glulisine [Apidra; Sanofi-Aventis]) are absorbed more swiftly from subcutaneous tissue, are active for a shorter time and restrict postprandial glucose fluctuations much more than regular human insulin (Rosenstock et al, 2000); they also reduce the number of episodes of severe hypoglycaemia (Owens et al, 2001; Dailey et al, 2004). In addition, the rapid-acting insulin analogues offer convenience as well as clinical benefits – they are injected immediately before a meal rather than 30–45 minutes in advance (Lepore et al, 2000).

The long-acting basal insulin analogue glargine (Lantus; Sanofi-Aventis), compared with regular short-acting insulin, helps achieve better HbA1c levels, improves fasting plasma glucose levels and postprandial glucose control, and reduces the risk of nocturnal hypoglycaemia (Pieber et al, 2000; Yki-Jarvinen et al, 2000).

In addition, insulin glargine has a stable metabolic profile that more closely mimics the action of endogenous insulin (Naess et al, 2004). Metabolic activity reaches a plateau 4 hours after its administration, remaining constant for 30 hours, whereas the time–action profile of traditional Neutral Protamine Hagedorn (NPH) insulin shows a pronounced peak after 4–6 hours followed by a decline (Heinemann et al, 2000). In addition, insulin glargine’s constant and peakless profile allows its flexible administration – whereas traditional insulins must be injected at bedtime – and it has a lower inter-subject variability than short-acting insulins, making accurate dosing and titration easier (Lepore et al, 2000).

Another long-acting insulin analogue, detemir (Levemir; Novo Nordisk), was released in the UK in June 2004 after the clinical phase of the author’s study had been conducted (Naess and Eriksen, 2002). Insulin detemir is currently licensed as part of a basal–bolus insulin regimen only (Novo Nordisk, 2005). Preliminary data suggest detemir, given twice daily, is associated with a reduced risk of nocturnal hypoglycaemia and weight gain compared with NPH in people with type 1 diabetes (Hermansen et al, 2001; Vague et al, 2003; Home et al, 2004).

An alternative regimen to basal–bolus for people with type 2 diabetes is twice-daily pre-mixed insulin in which traditional short- or rapid-acting insulin and intermediate-acting basal insulin are combined in one syringe. Modern pre-mixes manufactured using rapid-acting insulin analogues offer better postprandial control and are therefore replacing the traditional products (Garber, 2006). Despite their convenience for older people and people with visual impairment (Coscelli et al, 1992; McCormack and McElduff, 2004), such mixes do not closely match the profile of endogenous insulin and studies comparing them with a basal insulin and oral antidiabetic agent (OAD) combination have produced mixed findings (Janka et al, 2005). One study found more participants achieved glycaemic targets on a twice-daily pre-mix using biphasic insulin aspart (NovoMix 30; Novo Nordisk) than with once-daily glargine plus OADs (Raskin et al, 2005), although the number of minor hypoglycaemic episodes, weight gain and insulin doses were greater in the pre-mix group. Another study found that more individuals achieved target HbA1c levels with insulin glargine plus OADs than those on 30 % regular/70 % human NPH insulin. Participants on glargine plus OADs had fewer confirmed hypoglycaemic events than patients on 30/70 (Janka et al, 2005).

Management of wellbeing in diabetes care
Research has shown that people with diabetes report lower psychological wellbeing than those without reported disease (Naess et al, 2004); therefore, the maintenance or improvement of psychological outcomes is an important goal of diabetes care (Witthaus et al, 2001). As hyperglycaemia is associated with a greater incidence of vascular complications, improved glycaemic control could contribute to improved psychological wellbeing and vice versa, but a positive correlation cannot be assumed (Witthaus et al, 2001). Van der Does et al (1996) found higher HbA1c levels were significantly associated with higher symptom scores (which were obtained using a health outcome measures instrument specific to diabetes, developed by Grootenhuis and colleagues [1994]), worse mood and worse general wellbeing. Other, more controversial, findings found low levels of HbA1c related to low wellbeing (Naess et al, 1995).

Modern treatment regimens could improve psychological wellbeing; other contributory factors could include environmental factors, such as the changes in attitude towards people with chronic conditions and less stigmatisation, and the increase or reduction of complications (Naess and Eriksen, 2002). Naess and Eriksen (2002) are currently working to establish whether improved methods of diabetes control lead to improved psychological wellbeing and reduced co-morbidity.

Witthaus et al (2001) assessed treatment satisfaction and psychological wellbeing in 517 people with type 1 diabetes who were randomised to treatment with insulin glargine once daily, or NPH once or twice daily, depending on their previous regimen, with regular human insulin as the bolus component. Participants were asked to complete the Diabetes Treatment Satisfaction Questionnaire and the Wellbeing Questionnaire during clinic visits at baseline and at weeks 8, 20 or 28.

Treatment satisfaction improved with insulin glargine but deteriorated slightly with NPH. There was greater satisfaction with insulin glargine, regardless of previous regimen or injection device, and most emphasis was on treatment satisfaction items for ‘convenience’ and ‘desire to continue treatment’. Overall psychological wellbeing improved in both treatment groups.

Similar increases in treatment satisfaction have been reported from unblinded trials comparing insulin lispro with regular human insulin (Kotsanos et al, 1997). Indeed, those who reverted to regular insulin from lispro had marked reductions in treatment satisfaction, although these did not affect differences in responses concerning insulin glargine and NPH (Witthaus et al, 2001). Trials combining insulin glargine with a rapid-acting analogue may demonstrate improvement in treatment outcomes.

The Burton upon Trent experience
In the author’s hospital a total of 30 patients with long-standing type 1 diabetes and suspected poor glycaemic control – owing to their need for six or more specialist nurse interventions over the previous 2 years – were recruited and their glycaemic control was confirmed by HbA1c measurement before being switched from their existing regimens (twice-daily pre-mixes [using traditional ‘non-analogue’ insulins], or basal–bolus with ultralente or NPH) to a basal–bolus regimen using glargine as the basal insulin. There was no intentional randomisation and inclusion was determined solely on the participants’ previous need for specialist nurse intervention. If patients were already on a basal–bolus regimen, their rapid-acting insulin component was left unchanged. Those switching from twice-daily pre-mixes were prescribed insulin aspart as their bolus insulin. Therefore, all patients received insulin glargine plus either regular human insulin (Actrapid, Novo Nordisk) or one of two rapid-acting insulin analogues (lispro or aspart) available in the UK at the time of the study. At routine follow-up consultations, a number of patients commented on an improvement in their general wellbeing, prompting the author, in collaboration with consultant diabetologists Jonathan Benn and Andrew Willis, to devise a postal questionnaire. The questionnaire was designed to retrospectively establish patients’ perceived wellbeing before and after their regimen change.

A further 70 patients (giving N=100) were recruited from routine clinic appointments because of their poor glycaemic control or other management issues such as significant hypoglycaemic events. As before, participants were switched from existing regimens (either basal–bolus or twice-daily pre-mixes using traditional ‘non-analogue’ insulins) to insulin glargine which was added to their existing rapid-acting component: either regular human insulin soluble insulin or a rapid-acting insulin analogue. Of the 100 patients surveyed, 95 had type 1 diabetes (64 of whom were males) and five had type 2 diabetes (three of whom were males). The average age was 45.4 years, average duration of diabetes was 23.3 years and the mean HbA1c level was 9.21%.

The postal questionnaire was designed and sent out between 3 and 6 months after the regimen change. The questionnaire asked patients to rate their perceived wellbeing before and after the regimen change by circling the most appropriate words from a list describing positive and negative emotional states (Table 1). The questionnaire also asked about the frequency of hypoglycaemic episodes and whether management of blood glucose levels was any easier after the regimen change (Table 1). HbA1c levels after the regimen switch were measured at the individuals’ next clinic appointment between 3 and 6 months later.

The author’s diabetes centre manager, the consultant physician and the research manager were consulted regarding ethical approval. It was decided that ethical approval was not necessary as the clinical decision to change treatment regimens was made before the decision to conduct the study. The additional members of the group all required regimen changes due to poor glycaemic control. No randomisation of patients took place; the study was effectively a retrospective internal audit so it was felt that there were no ethical issues.

Comparison of clinic-measured HbA1c levels before and after the regimen change
A total of 79 participants had their HbA1c measurements taken before and after the regimen change (21 non-attendees), including 66 who switched from a basal–bolus regimen with traditional basal insulin (NPH or ultralente) and 13 formerly on twice-daily traditional insulin pre-mixes. Under the new basal–bolus regimen, with insulin glargine (basal) plus either an insulin analogue (insulins aspart or lispro) or regular human insulin (bolus), 42 patients received regular human insulin and 37 received either insulin aspart (n=28) or lispro (n=9). There was a significant improvement in HbA1c levels after the regimen change (P<0.001) regardless of previous regimen or bolus component (Tables 2 and 3).

There was a greater average reduction in HbA1c among those switching from twice-daily insulin pre-mixes than those switching from basal–bolus regimens (1.29 % compared with 0.96%; P<0.001), despite lower baseline HbA1c levels in the insulin pre-mix group. Those receiving bolus insulin analogues also experienced a greater average reduction in HbA1c than those receiving regular human insulin (1.16 % vs. 0.89%).

Questionnaire analysis
All of the 100 participants were sent the questionnaire; 75 individuals returned it.

Comparison of wellbeing before and after the regimen change
Respondents’ frequency of negative words was 115 and that of positive words was 35, which represents their perceived wellbeing before changing from their old regimen to a basal–bolus regimen with insulin glargine (basal) plus either an insulin analogue (insulins aspart or lispro) or regular human insulin as the bolus component (Table 4). After the regimen change, patients selected eight negative words and 131 positive words (Table 5). Comparison of the before and after estimates of wellbeing revealed that the regimen change resulted in a reduction in negative word selection of 93% (P<0.001) and an increase in positive word selection of 274 % (P<0.001).

Hypoglycaemia and managing blood glucose levels
Patients were invited to circle words (more than one if appropriate) that described their perception of their episodes of hypoglycaemia and the management of their blood glucose levels. Out of 75 respondents, the majority felt their hypoglycaemic events were ‘less frequent’ (n=40) or ‘no longer a problem’ (n=22), while nine felt they were the same and six reported more frequent events (Table 6).

Responses (n=72) to the question about managing blood glucose indicate that the majority of patients felt glycaemic control was better (n=69) or easier (n=63) to achieve after the regimen change, even including those whose glycaemic control deteriorated (n=5; mean increase in HbA1c=0.28%; data not shown). Management of glycaemic control remained the same as before for 13 patients; none reported deterioration in the management of their blood glucose (Table 7).

There was a significant improvement in HbA1c after the regimen change, regardless of whether a rapid-acting insulin analogue or regular human insulin was used as the bolus insulin. These results, along with the perceived reduction in hypoglycaemic events, agree with previous findings that insulin glargine effectively enables the achievement of glycaemic control and reduces hypoglycaemic events (Pieber et al, 2000; Riddle et al, 2003).

The increase in self-reported wellbeing after the regimen change suggests that better glycaemic control could contribute to an improvement in wellbeing. Many other variables may also influence wellbeing, including those related to diabetes (such as perceived reduction in hypoglycaemic episodes, easier management of diabetes and perceived flexibility of dosing) and those unrelated to diabetes (such as changing life circumstances). It must be noted that both wellbeing estimates were recorded at the same time after the regimen change; therefore, the pre-change wellbeing estimate was recorded retrospectively. This could compromise patient recall and, therefore, accuracy, so these findings should be interpreted with caution. It should also be noted that the survey questionnaire was devised at Queen’s Hospital and has not been scientifically validated. Further research using validated questionnaires is required to establish whether or not there is a relationship between improved glycaemic control, enhanced wellbeing and an insulin regimen change to a long-acting insulin analogue.

Implications of these findings for primary care practitioners
Fear of hypoglycaemic events is a major barrier to insulin initiation, for both patients and healthcare professionals, particularly in primary care, where prescribers are more likely to have limited experience. It is reassuring for prescribers that long-acting insulin analogues offer equivalent glycaemic control with a reduced risk of hypoglycaemia compared with NPH (Riddle et al, 2003; Chapman and Perry, 2005).

Physicians may find insulin glargine is especially helpful for patients who work shifts, where work patterns may be irregular, because its 24-hour action profile means it can be administered at any time of the day, as long as it is the same time each day (Riddle et al, 2003). Traditionally, long-acting insulin had to be administered at bedtime, but for shift workers who retire at 2200 hours one week and 0800 hours the next, for example, changing injection time to correspond with a variable bedtime can compromise glycaemic control. One of the author’s patients now administers insulin glargine at 1400 hours – the time he gets up when on night shift and a convenient time to inject when he works day shifts. In the author’s experience, patients on older long-acting insulins who alter their injection times may experience hyperglycaemic and hypoglycaemic episodes that they cannot adjust for. Insulin detemir does not afford this same flexibility because a once-daily dose (insulin detemir is sometimes administered twice daily) must be administered with the evening meal or at bedtime (RxList, 2006).

A regimen change from traditional insulin therapy to a basal–bolus approach using a long-acting insulin analogue plus a regular human insulin or rapid-acting insulin analogue bolus in people with diabetes and with poor glycaemic control improved HbA1c and enhanced self-reported wellbeing in this study population.

Amiel SA, Alberti KG (2004) Inhaled insulin. British Medical Journal 328(7450): 1215–6
Barrio Castellanos R (2005) Long-acting insulin analogues (insulin glargine or determir) and continuous subcutaneous insulin infusion in the treatment of type 1 diabetes mellitus in the paediatric population. Journal of Pediatric Endocrinology & Metabolism 18(Suppl 1): 1173–9
Barnett AH (2002) Completing the revolution – towards sustained euglycaemia in insulin therapy. Modern Diabetes Management 3(4): 2–8
Chapman TM, Perry CM (2005) Spotlight on insulin detemir in type 1 and type 2 diabetes mellitus. Biodrugs 19(1): 67–9
Coscelli C, Calabrese G, Fedele D, Pisu E, Calderini C, Bistoni S et al (1992) Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care 15(11): 1628–30
Dailey G, Rosenstock J, Moses RG, Ways K (2004) Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27(10): 2363–8
Garber AJ (2006) Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 66(1): 31–49
Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM (1994) Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabetic Medicine 11(3): 253–61
Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23(5): 644–9
Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M (2001) Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.Diabetes Care 24(2): 296–301
Home P, Bartley P, Russell-Jones D et al (2004) Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27(5): 1081–7
Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28(2): 254–9
Kotsanos JG, Vignati L, Huster W et al (1997) Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 20(6): 948–58
Kumar P, Clark M (1998) Clinical Medicine. 4th edition. Saunders (W.B.) Co Ltd, Edinburgh
Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49(12): 2142–8
McCormack A, McElduff A (2004) Update on insulin therapy. Australian Pharmacist 23(7): 520–6
Naess S, Eriksen J (2002) Studies in diabetes mellitus and psychological well-being in a Norwegian county. Quality of Life Newsletter 29: 12
Naess S, Eriksen J, Midthjell K, Tambs K (2004) Diabetes mellitus and psychological well-being. Change between 1984-1986 and 1995-1997. Journal of Diabetes and its Complications 18(3): 141–7
Naess S, Midthjell K, Moum T, Sorensen T, Tambs K (1995) Diabetes mellitus and psychological well-being. Results of the Nord-Trondelag health survey. Scandivanian Journal of Social Medicine 23(3): 179–88
Novo Nordisk (2005) Summary of product characteristics: Levemir Cartridge 100 U/ml, Levemir Pre-filled Pen 100 U/ml. Electronic Medicines Compendium, (accessed 01.03.2006)
Owens DR, Zinman B, Bolli GB (2001) Insulins today and beyond. Lancet 358(9283): 739–46
Pieber TR, Eugene-Jolchine I, Derobert E (2000) Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 23(2): 157–62
Raskin P, Allen E, Hollander P et al (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28(2): 260–5
Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26(11): 3080–6
Rosenstock J, Park G, Zimmerman J; U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group (2000) Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 23(8): 1137–42
RxList (2006) Insulin detemir dosage and administration. RxList Inc. Available at: (accessed 01.03.2006)
Vague P, Selam JL, Skeie S et al (2003) Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26(3): 590–6
Van der Does FE, De Neeling JN, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM, Heine RJ (1996) Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 19(3): 204-10
Witthaus E, Stewart J, Bradley C (2001) Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabetic Medicine 18(8): 619–25
Yki-Jarvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group (2000) Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23(8): 1130–6

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.